What changed for Polymyalgia Rheumatica
A plain English summary of what recently moved in the public data Voxsanity tracks for Polymyalgia Rheumatica. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 20 to 15 (-5)
- Trials on record 87 to 85 (-2)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Polymyalgia Rheumatica yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Polymyalgia Rheumatica that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04972968 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04972968) enrolled 181 adults in total across four groups: 50 received a placebo (a dummy injection), and 42, 45, and 44 received different doses of an investigational medicine called ABBV-154 (40 mg, 150 mg, and 340 mg, given as an injection under the skin). The trial was looking at polymyalgia rheumatica (PMR), a condition causing muscle pain and stiffness, and was mainly measuring how long it took before participants experienced a "flare" — meaning their symptoms returned and their doctor needed to increase their steroi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03600818 · results posted 10 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03600818) looked at a condition called polymyalgia rheumatica (PMR), which is an inflammatory condition causing pain and stiffness, mainly in the shoulders and hips. A total of 118 people took part — 58 received a placebo (an inactive treatment) alongside a standard 52-week course of the steroid prednisone that was gradually reduced over time, while 60 received an injection called sarilumab (200 mg every two weeks) alongside a shorter 14-week prednisone taper. The trial's main goal was to measure how many participants achi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03923738 · results posted 22 December 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03923738) enrolled 24 participants who received a medicine called TCZ (tocilizumab) given into a vein every four weeks. The trial ran in two periods — 22 participants completed the first period and all 22 went on to complete the second period. The trial was primarily measuring how the medicine moved through the body at two different doses (7 mg/kg and 6 mg/kg), as well as recording any unwanted events (called adverse events) that participants experienced. It also measured levels of two proteins in the blood — interleukin-6...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00556439 · results posted 26 February 2018
According to the results reported on ClinicalTrials.gov, this trial looked at two related conditions that cause inflammation of blood vessels — Giant Cell Arteritis (GCA) and Takayasu Arteritis (TAK). The trial had two stages. In the first stage (up to week 12), all participants received the study drug, abatacept: 49 people with GCA and 34 people with TAK. Those who responded and achieved remission (meaning their disease became inactive) then moved into the second, randomised stage, where they were randomly assigned — without knowing which they received — to either continue with abatacept or s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00836810 · results posted 5 February 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 people in total — 5 in the timed-release prednisone tablet group and 6 in the standard prednisolone group. One person in the timed-release group did not complete the trial; all 6 in the standard group finished. The trial was measuring changes in a substance in the blood called IL-6 (a chemical the body produces during inflammation), as well as self-reported morning stiffness, pain, and opinions of how the condition was affecting participants. Blood samples were taken at multiple time points across two nights — one...
-
NCT01396317 · results posted 17 January 2018
According to the results reported on ClinicalTrials.gov, this small trial (NCT01396317) enrolled 20 people with polymyalgia rheumatica (PMR) — a condition causing pain and stiffness, usually in the shoulders and hips. Ten participants received the drug tocilizumab alongside a tapering course of corticosteroids (steroid tablets that were gradually reduced over time), while the other ten received the corticosteroid taper on its own. The trial was measuring whether patients reached a state of "disease remission" — meaning their symptoms had settled and they were no longer taking steroids — at six...
-
NCT01364389 · results posted 4 March 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 16 people in total across three groups: 5 received ACZ885 (canakinumab), 6 received AIN457 (secukinumab), and 5 received prednisone (a steroid). The trial was measuring how well a single dose of each treatment reduced disease activity in people with polymyalgia rheumatica (PMR), a condition causing pain and stiffness, particularly in the shoulders and hips. Disease activity was tracked using a combined score called the PMR Activity Score, which drew on blood test results, morning stiffness, ability to lift the arms, p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a small amount of public research funding has been recorded for Polymyalgia Rheumatica, and the direction of that funding has been falling over time. This pattern suggests that Polymyalgia Rheumatica has not been a growing priority within publicly funded research in the United States. For patients, this may mean that the pace of publicly backed discovery is slower th...
See the full Polymyalgia Rheumatica page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.